Evogene Ltd.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-8.5M | $-16.5M | $-23.9M | $-26.6M | $-27.8M | $-23.4M | $-18.1M | $-20.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $591.0K | $713.0K | $842.0K | $759.0K | — | — | — | — |
| Amortization | — | $974.0K | $971.0K | $1.1M | $932.0K | $935.0K | $374.0K | — |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-13.5M | $-19.7M | $-21.6M | $-23.7M | $-24.7M | $-19.5M | $-17.7M | $-15.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $135.0K | $626.0K | $577.0K | $1.2M | $847.0K | $682.0K | $900.0K | $374.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $17.7M | $9.6M | $-4.5M | $13.3M | $-20.6M | $9.4M | $37.1M | $17.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-6.6M | $4.7M | $18.2M | $9.3M | $30.3M | $20.4M | $9.3M | $297.0K |
| Net Change in Cash | $-2.3M | $-5.5M | $-8.2M | $-3.3M | $-13.9M | $11.5M | $28.9M | $2.4M |
| Free Cash Flow | $-13.6M | $-20.3M | $-22.2M | $-24.8M | $-25.6M | $-20.2M | $-18.6M | $-15.5M |